Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis exec joins Genmab

Dr Judith Klimovsky becomes chief development officer

Copenhagen, Denmark-based Genmab has appointed Dr Judith Klimovsky as executive vice president and chief development officer.

Based out of the biotech's Princeton, US office, Dr Klimovsky will be responsible for the company's global product development strategy.

She joins Genmab from Novartis, where she most recently served as senior vice president and global head of oncology clinical development, having previously served as head of the global programme for cancer drug Afinitor.

Prior to this, Dr Klimovsky held director-level positions at Merck & Co in the US, and Bristol-Myers Squibb in South America.

Jan van de Winkel, Genmab's chief executive, said: “We are very pleased to welcome Judith to Genmab.

“She has a strong track record and skills in cancer drug development which will further strengthen the company as we build a winning team to continue our success in the future on the road to becoming a sustainably profitable biotech company.

“With Judith heading our product development efforts we will be able to bring forward truly differentiated products that have the potential to transform the treatment of cancer and provide great benefits to patients and their families in the future.”

10th February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...